France's pharmaceutical giant Sanofi, which has lagged rivals in producing new generation Covid-19 vaccines, has said it has decided to halt development of an mRNA candidate and focus on another vaccine against coronavirus.
Despite positive results at phase one and two trials, the candidate will not go to the third and final phase, Sanofi said, as they believed it would arrive too late to market with 12 billion anti-Covid doses already due to be produced by the end of the year.
Results from phase three trials of the other vaccine, developed with Britain's GlaxoSmithKline, are expected before the end of 2021.
The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant